- Age 18-75 years.
- Living donor/deceased donor kidney transplant recipients ≥6 months from time of transplant.
- Diagnosis of CABMR determined by kidney biopsy and the presence of HLA DSA using single-antigen bead-based assays.
- NOTE: If conducted within 12 months (+3 weeks) prior to the start of the screening period, and no intervening treatments have been administered, the biopsy does not need to be repeated at Screening. If conducted within 6 months (+ 3 weeks) prior to the start of Screening, the DSA analysis does not need to be repeated at screening. To be considered for determination of study eligibility, the biopsy and DSA analysis must be performed at least 2 months ± 2 weeks after the end of any prior treatment for ABMR (including CABMR) or TCMR, in order to show continuing CABMR and presence of HLA DSA. In addition, with the exception of steroids, treatments for ABMR or TCMR are not allowed within 3 months prior to the start of screening.
- The following histopathologic and serologic diagnostic criteria (based on Banff 2015 criteria [Loupy et al, 2017]) must be met for inclusion:
- Morphologic evidence of chronic tissue injury, as demonstrated by TG (cg>0). Biopsies without evidence of chronic tissue injury on light microscopy, but with glomerular basement membrane double contours on electron microscopy (cg1a) are eligible.
- Evidence of current/recent antibody interaction with vascular endothelium, including 1 or more of the following.
- Linear C4d staining in peritubular capillaries or medullary vasa recta (C4d2 or C4d3 by immunofluorescence on frozen sections, or C4d > 0 by immunohistochemistry on paraffin sections).
- At least moderate microvascular inflammation ([g + ptc] ≥ 2) in the absence of recurrent or de novo glomerulonephritis, although in the presence of acute TCMR, borderline infiltrate, or infection, ptc ≥ 2 alone is not sufficient and g must be ≥ 1.
- NOTE: The local pathologist's diagnosis must be reviewed by a central pathologist to confirm eligibility for entry into the study. Biopsies with other histopathologic changes (eg, BKV nephropathy or recurrent glomerulonephritis) may be eligible if concurrent CABMR changes (as detailed above) are present and determined to be the predominant cause of renal dysfunction.
- Serologic evidence of circulating DSA to HLA. NOTE: The local laboratory DSA results must be reviewed and confirmed by the central HLA reviewer during the screening period.
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
NCT03744910 | Phase 3 | Interventional
This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6 monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.
18 Years to 75 Years
If interested, contact firstname.lastname@example.org for more information
University of Alabama at Birmingham (UAB) University of Alabama Hospital (UAB Hospital)
Mayo Clinic Hospital
Keck Medical Center Of USC
Los Angeles,California,United States,90033
CedarsSinai Medical Center
Los Angeles,California,United States,90048
UCLA Kidney Transplant Research Program
Los Angeles,California,United States,90095
University of California Davis Medical Center
California Institute of Renal Research
San Diego,California,United States,92123
North America Research Institute
San Dimas,California,United States,91773
California Pacific Medical Center
San Francisco,California,United States,94109
San Francisco,California,United States,94118
University of California, San Francisco Medical Center
San Francisco,California,United States,94143
University Of Colorado Hospital Anschutz Medical Campus
Tampa General Medical Group
Northwestern Memorial Hospital
Rush University Medical Center University Cardiovascular Surgeons
Indiana University (IU) Health Physicians Kidney Diseases Clinic Medical Diagnostic Center Location
Unity Point Health
Des Moines,Iowa,United States,50309
Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics
Iowa City,Iowa,United States,52242
University of Louisville Research Foundation
Tulane University Health Sciences Center
New Orleans,Louisiana,United States,70112
Massachusetts General Cancer Center
Beth Israel Deaconess Medical Center
Henry Ford Health System
University of Minnesota
Washington University School of Medicine Infectious Diseases (WU ID) Clinic
Saint Louis,Missouri,United States,63110
University of Nebraska Medical Center
Saint Barnabas Medical Center
Livingston,New Jersey,United States,07039
Erie County Medical Center Corp.
Buffalo,New York,United States,14215
NYU Langone Medical Center
New York,New York,United States,10016
New York Presbyterian Hospital Weill Cornell Medical Center
New York,New York,United States,10021
Columbia University Medical Center
New York,New York,United States,10032
Duke Cancer Institute
Durham,North Carolina,United States,27710
Wake Forest University Health Sciences
Winston-Salem,North Carolina,United States,27157
The Ohio State University, Comprehensive Transplant Center
University of Cincinnati
Integris Baptist Medical Center
Oklahoma City,Oklahoma,United States,73112
Lehigh Valley Health Network
Central Pennsylvania Transplant Foundation
University of Pennsylvania
Jefferson University Hospital
Rhode Island Hospital
Providence,Rhode Island,United States,02906
Renal Disease Research Institute
UT Southwestern Medical Center
Methodist Healthcare System of San Antonio
San Antonio,Texas,United States,78229
University of Washington
University of Wisconsin School of Medicine and Public Health (UWSMPH)
Medical College of WI Froedtert Hospital
Royal Prince Alfred Hospital
WSLHD, Westmead Hospital
Princess Alexandra Hospital
The University of Queensland Princess Alexandra Hospital (PAH)
Monash Health Monash Medical Centre
The Royal Melbourne Hospital
Sir Charles Gairdner Hospital (SCGH)
Vancouver General Hospital Gordon & Leslie Diamond Centre
St. Paul's Hospital, Providence Health Care, Univ. Of British Columbia
Shared Health Inc. operating as the Health Sciences Centre
Queen Elizabeth II Health Sciences Centre
London Health Sciences Centre
St. Michael's Health Centre
McGill University Health Center
St Paul's Hospital Foundation
CHU GRENOBLE ALPES Consultation Nphrologie Bureau des ARC (Ct Chartreuse, RezdeChausse Haut)
Nphrologie Pavillon Sainte Venise CHU de Rouen Hpital de Bois Guillaume
Centre Hospitalier Universitaire (CHU) de Bordeaux Groupe Hospitalier Pellegrin
Centre Hospitalier Universitaire (CHU) Hopital Henri Mondor
Hopital Kremlin Bicetre
Centre Hospitalier Universitaire (CHU) De Limoges Hopital Dupuytren
Hopital Edouard Herriot
Centre Hospitalier Regional Universitaire (CHRU) Montpellier Arnaud de Villeneuve
CHU de Nantes Houtel Dieu
Nantes Cedex 1,France,44093
Centre Hospitalier Universitaire de Nice, Hopital Pasteur
Nice Cedex 1,France,06001
Hospital SaintLouis APHP
Hopital Necker Enfants Malades
Centre Hospitalier Universitaire de Poitiers
Hopitaux Universitaire de StrasbourgCentre de References des Maladies Autoimmunes
Centre Hospitalier Regional Universitaire de Tours (CHRU de Tours) Hopital Bretonneau
Tours Cedex 9,France,37044
Charite Universitaetsmedizin Berlin Campus Charite Mitte (CCM)
Debreceni Egyetem, Klinikai Kzpont, Auguszta
Amsterdam University Medical Center (Amsterdam UMC), Academic Medical Center (AMC)
Amsterdam UMC location AMC
University Medical Center Groningen
Leiden University Medical Center (LUMC)
Maastricht University Medical Centre
Hospital Del Mar
Hospital Vall d'Hebron
Hospital Clinic Barcelona
Hospital Universitari de Bellvitge
Hospital Universitario Ramon y Cajal
Hospital Clinico San Carlos
Hospital Universitario de OctubreCentro de Actividades Ambulatorias
Hospital Universitario Marques De Valdecilla
Centro Hospital Universitario Dr. Preset
Hospital Universitario Miguel Servet
Karolinska University Hospital
Uppsala Universitet Akademiska Sjukhuset
Study Eligibility Criteria
- Multi-organ transplant recipient (except for simultaneous kidney-pancreas or previous multiple kidney transplants) or cell transplant (islet, bone marrow, stem cell) recipient.
- Treatment for ABMR (including CABMR) or TCMR within 3 months prior to the start of screening with the exception of steroids.
- Received T cell depleting agents (e.g., alemtuzumab, anti-thymocyte globulin) within 3 months prior to the start of screening.
- Pregnant, breastfeeding, or unwillingness to practice adequate contraception.
- Active tuberculosis (TB) or history of active TB.
- History of human immunodeficiency virus (HIV) infection or positive for HIV.
- Seropositive for hepatitis B surface antigen (HBsAg)
- Hepatitis C virus (HCV) RNA positive.